Current issues in ER and HER2 testing by IHC in breast cancer.
about
In vitro comparative models for canine and human breast cancersAdvances in the Molecular Analysis of Breast Cancer: Pathway Toward Personalized MedicineImmunohistochemical expression of CXCR4 on breast cancer and its clinical significanceThe future role of personalized medicine in the treatment of glioblastoma multiformeHER2 targeted molecular MR imaging using a de novo designed protein contrast agentThe use of sensitive chemical antibodies for diagnosis: detection of low levels of EpCAM in breast cancerDetection of metastatic tumors after γ-irradiation using longitudinal molecular imaging and gene expression profiling of metastatic tumor nodulesBiosensors: the new wave in cancer diagnosis.Estrogen Receptor-Targeted Contrast Agents for Molecular Magnetic Resonance Imaging of Breast Cancer Hormonal Status.Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis.Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimensLack of prognostic significance of adiponectin immunohistochemical expression in patients with triple-negative breast cancer.Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications.Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER statusDNA aptamer evolved by cell-SELEX for recognition of prostate cancer.Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis.Prognostic association of YB-1 expression in breast cancers: a matter of antibody.Incorporating tumour pathology information into breast cancer risk prediction algorithms.MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.GoIFISH: a system for the quantification of single cell heterogeneity from IFISH images.A population-based study of Kurdish breast cancer in northern Iraq: hormone receptor and HER2 status. A comparison with Arabic women and United States SEER data.Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens.Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.Predictive biomarkers and companion diagnostics. The future of immunohistochemistry: "in situ proteomics," or just a "stain"?Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancerMolecular portrait-based correlation between primary canine mammary tumor and its lymph node metastasis: possible prognostic-predictive models and/or stronghold for specific treatments?Cytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours.Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).Prediction of individual response to anticancer therapy: historical and future perspectivesImmunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches.Role of estrogen in thyroid function and growth regulation.The effect of freezing on the immunoprofile of breast carcinoma cells.Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study.Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association ConsortiumStandardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells.HER-2 assessment in formalin-fixed paraffin-embedded breast cancer tissue by well-based reverse phase protein arrayHER2/neu Immunostaining in Invasive Breast Cancer: Analysis of False Positive Factors.Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients.
P2860
Q26752714-6A898354-C7A2-407C-9E60-9B07C51EB47AQ27001994-D3A5570D-D29E-4F72-88E5-5E5674948C5CQ27011420-E4F986DA-447B-458A-A11F-CB02FD064900Q28391635-1159B48D-CD40-441E-B2CE-24C948DB01C6Q28477503-7EA83638-35F3-4691-9B67-731F5D089BB1Q28486906-AC7BB972-A23E-4584-BE9E-8EB7A8624AC0Q30388141-0AE66610-1BEF-4D28-AD30-C0F896807EC2Q30447534-77B73B7A-6410-4ED5-B0B7-2104E08448A0Q31097623-D69102E1-D1DD-43DB-8792-0BFE9E145456Q33454999-2A0B17F7-140D-486F-A200-9AD26A779F83Q33559365-FF130947-C87E-4501-A4B5-8AB561ABEF31Q33683673-1E6DE786-9709-4990-85D2-E7B766953309Q33699614-AD36AC7D-79FB-47E1-8906-F8819C8C3390Q33739397-687530B1-F420-472D-BAD4-33BABFBE0457Q33739841-749E294F-19C8-4DF8-8095-33A2EFECB524Q33769803-4F7E6F86-21F2-4D99-8E59-3B35D124B18DQ33793416-914E5B1E-9C59-4CFB-99F5-A1AE28FD6845Q33859673-318AB562-C06B-440F-BDA4-9FFA8510F746Q33939605-FFC32525-4FB8-4649-AF87-190A68F569D6Q34048046-C8F7D495-A094-4919-BF1C-9AE4FF4A81A1Q34138714-36A44CFA-8BEC-4D09-8AB6-FF747FCD675DQ34202981-6E744209-4403-49B7-BF10-A01ED0C76935Q34315367-478AC110-7ACF-4980-9ADF-DD0FF5A8AFACQ34342079-0F5FCDA3-5BEB-450E-B9DF-1DC10DC1B988Q34344198-6C8C5AAC-BAFF-4554-B746-33C04583CCF9Q34434447-394002CD-8927-4FDC-BC16-6C041BC4285EQ34446385-A7B796AE-E3B7-4C44-AA08-CDBA10CE768CQ34475233-E1C781DF-C4DE-4C60-9BA6-CD1BA9C29BCBQ34543740-4BDEE370-2AF0-4851-BC3E-7A36221622D0Q34613506-ADDB9D76-DED7-4490-97D0-4BC015B9B7DCQ35024682-5130ED69-46B0-4E4D-8BF9-32E9455CF8B1Q35034555-17B90B64-CAB1-44D0-910A-B346BF42245FQ35039670-6F623E1D-B080-4B57-8C4D-A15C74A32F15Q35053377-FBB989CF-C636-418F-8CAB-FAC126E255DCQ35078787-F3198326-6A3E-46F4-B507-BCBF6466A5ACQ35119701-38E8ED84-E836-467B-BA72-D0698FF97C79Q35170197-0F6C6550-8199-4E35-8CA8-C09782CD6EB7Q35184966-7C8FDE7C-0C59-42B5-9102-2A291D12CF99Q35323892-DAD0DFA6-A784-4CE7-AA4F-69EC18729B24Q35735913-DF6657AD-1378-4485-9AE6-3E993C54C7F1
P2860
Current issues in ER and HER2 testing by IHC in breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current issues in ER and HER2 testing by IHC in breast cancer.
@en
Current issues in ER and HER2 testing by IHC in breast cancer.
@nl
type
label
Current issues in ER and HER2 testing by IHC in breast cancer.
@en
Current issues in ER and HER2 testing by IHC in breast cancer.
@nl
prefLabel
Current issues in ER and HER2 testing by IHC in breast cancer.
@en
Current issues in ER and HER2 testing by IHC in breast cancer.
@nl
P2860
P1433
P1476
Current issues in ER and HER2 testing by IHC in breast cancer.
@en
P2093
Allen M Gown
P2860
P2888
P304
P356
10.1038/MODPATHOL.2008.34
P478
21 Suppl 2
P577
2008-05-01T00:00:00Z